[go: up one dir, main page]

MX2008002161A - Anticuerpos quimericos con regiones de primate del nuevo mundo. - Google Patents

Anticuerpos quimericos con regiones de primate del nuevo mundo.

Info

Publication number
MX2008002161A
MX2008002161A MX2008002161A MX2008002161A MX2008002161A MX 2008002161 A MX2008002161 A MX 2008002161A MX 2008002161 A MX2008002161 A MX 2008002161A MX 2008002161 A MX2008002161 A MX 2008002161A MX 2008002161 A MX2008002161 A MX 2008002161A
Authority
MX
Mexico
Prior art keywords
regions
new world
chimeric antibodies
world primate
cdr
Prior art date
Application number
MX2008002161A
Other languages
English (en)
Inventor
Philip Anthony Jennings
Anthony Gerard Doyle
Adam William Clarke
Original Assignee
Arana Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005904406A external-priority patent/AU2005904406A0/en
Application filed by Arana Therapeutics Ltd filed Critical Arana Therapeutics Ltd
Publication of MX2008002161A publication Critical patent/MX2008002161A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion proporciona un anticuerpo quimerico o una porcion que enlaza antigeno del mismo. La porcion que enlaza antigeno comprende por lo menos dos regiones de complementariedad (CDR) y por lo menos tres regiones de estructura, en donde por lo menos una CDR es una CDR de primate del Nuevo Mundo.
MX2008002161A 2005-08-15 2006-08-15 Anticuerpos quimericos con regiones de primate del nuevo mundo. MX2008002161A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2005904406A AU2005904406A0 (en) 2005-08-15 New World Antibodies
PCT/AU2006/001166 WO2007019621A1 (en) 2005-08-15 2006-08-15 Chimeric antibodies with new world primate regions

Publications (1)

Publication Number Publication Date
MX2008002161A true MX2008002161A (es) 2008-04-22

Family

ID=37757238

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008002161A MX2008002161A (es) 2005-08-15 2006-08-15 Anticuerpos quimericos con regiones de primate del nuevo mundo.

Country Status (13)

Country Link
EP (1) EP1945669A4 (es)
JP (1) JP2009504686A (es)
KR (1) KR20080068005A (es)
CN (2) CN101287763A (es)
AU (1) AU2006281981A1 (es)
BR (2) BRPI0614867A2 (es)
CA (1) CA2619245A1 (es)
MX (1) MX2008002161A (es)
NO (1) NO20080800L (es)
NZ (1) NZ565904A (es)
RU (1) RU2008110058A (es)
WO (1) WO2007019621A1 (es)
ZA (2) ZA200802247B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5102028B2 (ja) 2004-07-26 2012-12-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｃｄ１５４抗体
BRPI0707425A2 (pt) 2006-02-01 2011-05-03 Arana Therapeutics Ltd construção de anticorpo de domìnio, molécula isolada de ácido nucleico, composição farmacêutica, e, métodos para detectar tnf-alfa humano em uma amostra, e para tratar um distúrbio
BRPI0809042B1 (pt) * 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
WO2010017595A1 (en) * 2008-08-14 2010-02-18 Arana Therapeutics Limited Variant domain antibodies
RU2517085C2 (ru) * 2010-08-06 2014-05-27 Олег Ильич Эпштейн Комплексное лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2502521C2 (ru) * 2010-08-06 2013-12-27 Олег Ильич Эпштейн Комплексное лекарственное средство для лечения бактериальных инфекций и способ лечения бактериальных инфекций
RU2516931C2 (ru) * 2010-08-06 2014-05-20 Олег Ильич Эпштейн Способ и композиция для профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2519862C2 (ru) * 2010-08-06 2014-06-20 Олег Ильич Эпштейн Комплексное лекарственное средство и способ профилактики и лечения инфекционных вирусных заболеваний
RU2521392C2 (ru) * 2010-08-06 2014-06-27 Олег Ильич Эпштейн Комплексное лекарственное средство для лечения вирусных заболеваний и способ лечения вирусных заболеваний
RU2505312C2 (ru) * 2010-08-06 2014-01-27 Олег Ильич Эпштейн Комплексное лекарственное средство для лечения гриппа различных типов
RU2577299C2 (ru) * 2011-07-04 2016-03-10 Олег Ильич Эпштейн Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний
RU2535034C2 (ru) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2535033C2 (ru) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
RU2579262C1 (ru) * 2014-10-02 2016-04-10 Мапикс Эс.Эй.Ар.Эл. Лекарственное средство для лечения инфекционных заболеваний
CL2015002152A1 (es) * 2015-07-31 2016-06-03 Pontificia Universidad Católica De Chile Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnostico de la infección causada por vrsh

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT70272A (en) * 1991-07-25 1995-09-28 Idec Pharma Corp Recombinant antibodies for human therapy
US6569431B2 (en) * 2000-10-17 2003-05-27 The Regents Of The University Of California Recombinant antibody fragments as autoantibody antagonists
US7235643B2 (en) * 2000-11-07 2007-06-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with high affinity
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US20070212301A1 (en) * 2003-11-07 2007-09-13 Amgen, Inc. Monkey Immunoglobulin Sequences

Also Published As

Publication number Publication date
CN101287763A (zh) 2008-10-15
ZA200802247B (en) 2009-08-26
NZ565904A (en) 2012-02-24
JP2009504686A (ja) 2009-02-05
RU2008110058A (ru) 2009-09-27
EP1945669A4 (en) 2009-07-22
EP1945669A1 (en) 2008-07-23
KR20080068005A (ko) 2008-07-22
BRPI0614430A2 (pt) 2011-03-29
ZA200802246B (en) 2009-09-30
CA2619245A1 (en) 2007-02-22
AU2006281981A1 (en) 2007-02-22
NO20080800L (no) 2008-05-09
BRPI0614867A2 (pt) 2012-01-31
CN101287762A (zh) 2008-10-15
WO2007019621A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
MX2008002161A (es) Anticuerpos quimericos con regiones de primate del nuevo mundo.
WO2007019620A8 (en) Engineered antibodies with new world primate framework regions
IL212949A0 (en) Humanized anti-cd4 antibody capable of activating cd4+ cd25+ regulatory t celle
WO2007129895A3 (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
WO2006096491A3 (en) Anti-ctla-4 antibody compositions
ATE452147T1 (de) Antikörper mit korrigierten cdr
NZ602294A (en) Monoclonal antibodies against c-met
IL191217A (en) Anti-17 mantle monoclonal antibody
NZ611269A (en) Neutralizing anti-ccl20 antibodies
WO2006031653A3 (en) Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
WO2007008943A3 (en) Optimized anti-ep-cam antibodies
WO2008048970A3 (en) Synthetic antibodies
WO2007120334A3 (en) Methods and compositions for targeting polyubiquitin
PL2218737T3 (pl) Humanizowane przeciwciała anty-NGF
RS53120B (en) ANTAGONISTIC HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE HUMAN LIGHT
EP2233501A4 (en) HUMANIZED MONOCLONAL ANTI-CD34 ANTIBODIES AND THEIR PREPARATION AND APPLICATIONS
WO2006039258A3 (en) Human antibodies against parathyroid hormone
WO2008110914A3 (en) Methods for producing active scfv antibodies and libraries therefor
WO2007149932A3 (en) Methods and compositions for targeting hepsin
WO2008052108A3 (en) Methods for use in human-adapting monoclonal antibodies
WO2007002525A3 (en) Tomoregulin antibodies and uses thereof
WO2007002096A3 (en) Methods and compositions for targeting ifnar2
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
WO2007072022A3 (en) Composition comprising an antigen-recognizing molecule and a lipid-based carrier
TW200742745A (en) Monoclonal antibody specific to enrofloxacin, hybridoma producing same and kit comprising same

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FA Abandonment or withdrawal